• An investigation was carried out to determine the mechanism by which MK-507 (L-671,152), a water-soluble inhibitor of human carbonic anhydrase II in vitro, reduces intraocular pressure when applied topically to monkey eyes. Intraocular pressure, tonographically measured outflow facility, and fluorophotometrically determined aqueous humor flow were measured before and after therapy in eight normal cynomolgus monkeys. Fifty microliters of 2% MK-507 was instilled in one eye and diluent in the contralateral eye. Baseline values for intraocular pressure, outflow facility, and aqueous humor flow were similar in the drug-treated and diluent-treated control eyes. After therapy, intraocular pressure was significantly (P<.05) reduced from 1 to 7 hours (eg, 14.0±1.0 and 15.9±0.9 mm Hg [mean±SEM], treated and control eyes, respectively, at 3 hours). Outflow facility was not significantly (P>.40) changed at 3 hours, and aqueous humor flow measured over 5 hours was significantly (P<.05) reduced (38%) in treated (0.9±0.1 μL/min) as compared with control eyes (1.5±0.1 μL/min). The results suggest that MK-507 reduces intraocular pressure by decreasing aqueous humor production.
Wang R, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys. Arch Ophthalmol. 1991;109(9):1297–1299. doi:10.1001/archopht.1991.01080090123036
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: